All Press Releases for November 11, 2020

Biom Therapeutics LLC Selected as Finalist at BioFlorida's Annual Biopitch Competition For Early-Stage Life Science Companies

Biom Therapeutics receives prestigious recognition at BioFlorida annual conference.



"Biom Therapeutics is committed to improving the lives of Floridians and other people around the globe who are coping with the daily challenges of hard-to-treat neurological diseases."

    SARASOTA, FL, November 11, 2020 /24-7PressRelease/ -- Biom Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapeutics for childhood developmental and epilepsy disorders, announced its recognition as a finalist in BioPitch, an annual competition for early-stage life science companies at BioFlorida. This exciting competition offers a platform for the Sunshine State's most innovative companies and the opportunity to pitch to life science investors.

Bobban Subhadra, CEO of Biom Therapeutics, remarked, "We are grateful for everyone's vote during the BioPitch competition at BioFlorida. Being nominated as one of three finalists from a pool of 50 companies speaks to the compelling investment opportunity and value evident to all individuals who voted for us. We appreciate the recognition of our mission's importance and our rapid progress in medical research."

At this past week's competition, innovative entrepreneurs pitched their company's activities to leading authorities in Florida's biotech industry in a digital format. The event was chaired by Robert P. Mino, a registered patent attorney, and sponsored by Fisher Scientific. BioPitch investors come from investment firms such as HealthQuest Capital, New World Angels, Beacon Capital, and Cleveland Clinic Innovations. Participants' pitches were evaluated by an expert panel of judges representing well-respected firms such as Florida Funders, HealthQuest Capital, Capitala Group.

Angel investors are an important source of funding for new companies engaged in biotech research. Without their critical injections of capital, early-stage life science companies may exhaust their resources before completing their mission.

Mr. Subhadra also noted, "Biom Therapeutics is committed to improving the lives of Floridians and other people around the globe who are coping with the daily challenges of hard-to-treat neurological diseases."

About BIO Florida
BioFlorida is the voice of Florida's life sciences industry, representing 6,700 establishments and research organizations in the biopharmaceuticals, medical technology, health IT, and bioagriculture sectors that collectively employ nearly 94,000 Floridians. Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors, and service providers. www.bioflorida.com

About Biom Therapeutics
Biom Therapeutics is a clinical-stage biopharmaceutical company founded by a team of business leaders, scientists, and clinicians that develops therapeutics for hard-to-treat neurological diseases. Biom Therapeutics is emerging as a world-class biotech firm that improves human health and quality of life by developing innovative drugs for treating and potentially reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer's disease, and autism. The firm's initial focus is on rare pediatric epilepsy, including developmental and epileptic encephalopathies and Angelman syndrome. Our talented team of scientists, scientific advisors, and board directors works diligently to accelerate breakthrough treatments for patients with significant unmet medical needs. www.biomtherapeutics.com

Investor / Media Contact:
John Allen
info@biomtherapeutics.com
941-552-8417

# # #

Contact Information

John Allen
Biom Therapeutics LLC
Sarasota, Florida
United States
Voice: 941-552-8417
E-Mail: Email Us Here
Website: Visit Our Website